Transthyretin Amyloid CardiomyopathySymptoms, Doctors, Treatments, Advances & More
Learn About Transthyretin Amyloid Cardiomyopathy
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Cleveland Clinic Main Campus
Mazen Hanna is a Cardiologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 33 years. Dr. Hanna is rated as an Elite provider by MediFind in the treatment of Transthyretin Amyloid Cardiomyopathy. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Cardiac Amyloidosis, Transthyretin Amyloid Cardiomyopathy, Primary Amyloidosis, Heart Transplant, and Tenotomy.
Boston Medical Center Outpatient Pharmacy
Frederick Ruberg is a Cardiologist practicing medicine in Boston, Massachusetts. Dr. Ruberg is rated as an Elite provider by MediFind in the treatment of Transthyretin Amyloid Cardiomyopathy. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Primary Amyloidosis, Cardiac Amyloidosis, Transthyretin Amyloid Cardiomyopathy, Heart Transplant, and Cardiac Ablation.
Brigham And Women's Hospital
Rodney Falk is a Cardiologist practicing medicine in Boston,, Massachusetts. Dr. Falk is rated as an Elite provider by MediFind in the treatment of Transthyretin Amyloid Cardiomyopathy. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Primary Amyloidosis, Cardiac Amyloidosis, Transthyretin Amyloidosis, Heart Transplant, and Cardiac Ablation.
Summary: This is a single center prospective study evaluating 124I-evuzumitide in patients with systemic amyloidosis. The purpose of this study is to 1) Establish the diagnostic accuracy of 124I-evuzumitide in cardiac amyloidosis 2) Evaluate extracardiac uptake 3) identify and characterize the distribution and uptake of 124I-evuzumitide in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and 4)...
Summary: The study is conducted in participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a heart disease that occurs in people with the disease ATTR amyloidosis. The purpose of this study is to see how radioactively labelled coramitug is taken up by the heart after administration through an infusion (Cohort 1), and to understand the extent to which coramitug can be displaced by radioactively la...